William D. Waddill, Director, on June 23, 2026, sold 9,000 shares in Protagonist Therapeutics (PTGX) for $1,061,460. Following the Form 4 filing with the SEC, Waddill has control over a total of 7,825 common shares of the company, with 7,825 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1377121/000110465926077761/xslF345X05/tm2618679-1_4seq1.xml
Juan C. Jaen, President, on June 22, 2026, sold 31,431 shares in Arcus Biosciences (RCUS) for $877,501. Following the Form 4 filing with the SEC, Jaen has control over a total of 1,269,100 common shares of the company, with 378,291 shares held directly and 890,809 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1724521/000161071726000294/xslF345X05/form4.xml
Anthony Mathew Eisen, Director, on June 22, 2026, sold 18,000 shares in Block (XYZ) for $1,323,480. Following the Form 4 filing with the SEC, Eisen has control over a total of 1,940,672 Class A common shares of the company, with 1,940,672 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1512673/000162828026045296/xslF345X05/wk-form4_1782336968.xml
Chin-Chi Teng, Senior Vice President, on June 22, 2026, sold 4,500 shares in Cadence Design Systems (CDNS) for $1,731,970. Following the Form 4 filing with the SEC, Teng has control over a total of 145,281 common shares of the company, with 145,281 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/813672/000081367226000082/xslF345X05/wk-form4_1782336804.xml